Yunqi Capital Opposes STAAR's Sale to Alcon at $30.75
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 57 minutes ago0mins
- Shareholder Opposition: Yunqi Capital, holding a 5.1% stake in STAAR, firmly opposes the sale at $30.75 per share, asserting that it is not the right time to sell the company and that the deal fails to maximize shareholder value.
- Inopportune Market Timing: Yunqi Capital emphasizes that STAAR is at a strategic inflection point, with demand indicators in the Chinese market showing signs of recovery, suggesting that selling now would forfeit future growth opportunities.
- Transaction Structure Issues: Yunqi Capital criticizes STAAR's go-shop process as being designed to secure the deal with Alcon rather than genuinely seeking alternative bids, thereby limiting potential buyers' participation.
- Lack of Transparency: Yunqi Capital questions STAAR's failure to communicate transparently with shareholders, particularly regarding the roles and decisions of management and the board during the go-shop process, which undermines shareholder trust.
ALC.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 93.78 USD with a low forecast of 80.00 USD and a high forecast of 112.74 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 78.870
Low
80.00
Averages
93.78
High
112.74
Current: 78.870
Low
80.00
Averages
93.78
High
112.74
Canaccord
William Plovanic
Hold
maintain
$28
2025-12-10
New
Reason
Canaccord
William Plovanic
Price Target
$28
2025-12-10
New
maintain
Hold
Reason
Canaccord analyst William Plovanic raised the firm's price target on Staar Surgical (STAA) to $30.75 from $28 and keeps a Hold rating on the shares. The firm noted Alcon (ALC) announced this morning an amended merger agreement with Staar Surgical, where the they have increased its acquisition price to $30.75 from previous $28, a 10% increase in its bid.
Wells Fargo
Simran Kaur
Equal Weight
maintain
$28
2025-12-10
New
Reason
Wells Fargo
Simran Kaur
Price Target
$28
2025-12-10
New
maintain
Equal Weight
Reason
Wells Fargo analyst Simran Kaur raised the firm's price target on Staar Surgical to $30.75 from $28 and keeps an Equal Weight rating on the shares. The firm notes Alcon (ALC) announced it is increasing its bid price for Staar (STAA) from $28/share to $30.75/share, or a total equity value of $1.6B. Vote is expected next Friday.
Citi
Veronika Dubajova
Buy
downgrade
2025-11-28
Reason
Citi
Veronika Dubajova
Price Target
2025-11-28
downgrade
Buy
Reason
Citi analyst Veronika Dubajova lowered the firm's price target on Alcon to CHF 90 from CHF 91 and keeps a Buy rating on the shares.
Baird
Jeff Johnson
Outperform
maintain
$95 -> $98
2025-11-13
Reason
Baird
Jeff Johnson
Price Target
$95 -> $98
2025-11-13
maintain
Outperform
Reason
Baird analyst Jeff Johnson raised the firm's price target on Alcon to $98 from $95 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results leading to increased conviction in 2026.
See All Ratings
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors are driving the growth of the intraocular lens market?
How are technological advancements improving visual outcomes in the IOL market?
What is the projected market size of intraocular lenses by 2033?
How might the aging population impact the IOL market in the future?